<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751631</url>
  </required_header>
  <id_info>
    <org_study_id>EYN-MYD-TP-31</org_study_id>
    <nct_id>NCT03751631</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation</brief_title>
  <acronym>MIST-1</acronym>
  <official_title>A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyenovia Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyenovia Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates pupil dilation using fixed combination phenylephrine-tropicamide vs.
      phenylephrine only and tropicamide only. Participants must attend 3 visits where 1 of the 3
      study drugs will be administered to both eyes. Afterwards, pupil dilation and safety
      assessments will be performed at specific time intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteer participants will be screened for study eligibility during a Screening Visit and
      enrolled after signing the study-specific informed consent form. Subjects meeting all
      inclusion/exclusion criteria will be scheduled for 3 treatment visits, which must occur at
      least 2 days, but no more than 7 days apart. At each treatment visit, baseline measurements
      will be taken, then 1 of the 3 study drugs will be administered to both eyes. Afterwards,
      efficacy and safety assessments will be performed at specific time intervals. Study drug
      administration for each subject will be equally randomized to 1 of 6 possible sequences of
      study drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Actual">January 11, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This trial is a double-masked, active-controlled, cross-over superiority study evaluating the efficacy of the fixed combination study drug vs. the 2 individual components in the fixed combination drug.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>There will be no differences in the presentation of study drug administered and all study personnel conducting ophthalmic assessments after study drug administration will be masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pupil diameter</measure>
    <time_frame>Baseline and 35 minutes after initial dose</time_frame>
    <description>Difference in pupil diameter vs. baseline measured in highly photopic conditions</description>
  </primary_outcome>
  <other_outcome>
    <measure>Eyelid erythema</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Eyelid erythema evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Eyelid edema</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Eyelid edema evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Conjunctival hyperemia</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Conjunctival hyperemia evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Conjunctival edema</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Conjunctival edema evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sclera appearance</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Scleral appearance evaluated using slit lamp biomicroscopy; categories are &quot;normal&quot; and &quot;abnormal&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal edema</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Corneal edema evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal staining</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Corneal staining evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (normal) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anterior chamber cells</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Anterior chamber cells evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (none) to 4 (hypopyon)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anterior chamber flare</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Anterior chamber flare evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (none) to 3 (milky aqueous)</description>
  </other_outcome>
  <other_outcome>
    <measure>Iris appearance</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Iris appearance evaluated using slit lamp biomicroscopy; categories are &quot;normal&quot; and &quot;abnormal&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Lens opacity</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Lens opacity evaluated using slit lamp biomicroscopy and a numeric grading scale ranging from 0 (none) to 3 (dense)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anterior vitreous appearance</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Anterior vitreous appearance evaluated using slit lamp biomicroscopy; categories are &quot;normal&quot; and &quot;abnormal&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Basline, 5 minutes and 180 minutes after initial dose</time_frame>
    <description>Untoward medical occurrences</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline and 65 minutes after initial dose</time_frame>
    <description>Intraocular pressure measured by tonometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline and 180 minutes after initial dose</time_frame>
    <description>Visual acuity measured using ETDRS lighted chart</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Mydriasis</condition>
  <arm_group>
    <arm_group_label>Phenylephrine-tropicamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine 2.5% ophthalmic solution administered using a microdose dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tropicamide 1% ophthalmic solution administered using a microdose dispenser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine 2.5%-tropicamide 1% ophthalmic solution</intervention_name>
    <description>Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Phenylephrine-tropicamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine 2.5% ophthalmic solution</intervention_name>
    <description>Phenylephrine 2.5% ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropicamide 1% ophthalmic solution</intervention_name>
    <description>Tropicamide 1% ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Tropicamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written consent and return for all study visits

          -  Photopic pupil diameter &lt;= 3.5 mm in each eye

        Exclusion Criteria:

          -  Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride

          -  History of benign prostatic hyperplasia

          -  Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant,
             anticonvulsant, or cholinergic drug

          -  History of closed-angle glaucoma

          -  Anatomically narrow anterior chamber angles

          -  Ocular surgery or laser treatment of any kind

          -  History of chronic or acute uveitis

          -  History of traumatic iritis or hyphema

          -  History of traumatic mydriasis or angle recession

          -  History of heterochromia

          -  Irregularly-shaped pupil secondary to ocular trauma or congenital defect.

          -  History of neurogenic pupil disorder

          -  History of anterior chamber intraocular lens (IOL) or iris-fixated IOL

          -  History of iris surgery, iris atrophy, or iris-cornea apposition/touch

          -  Unwilling or unable to discontinue use of contact lenses at treatment visits.

          -  Current active eye disease for which topical or systemic ophthalmic medication is
             necessary, except for dry eye disease managed using artificial tears.

          -  Presence of a severe/serious ocular condition, or any other unstable medical condition
             that, in the Investigator's opinion, may preclude study treatment and/or follow-up

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsontcho Ianchulev, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eyenovia Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <disposition_first_submitted>January 31, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 7, 2020</disposition_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

